Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ImmunityBio, Inc. entered into stock purchase agreement (the “SPA”) with certain institutional investors (the “Investors”) valued at approximately $40.0 million (effective 2023-07-20).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional investors (the “Investors”)
- Value
- approximately $40.0 million
- Effective
- 2023-07-20
Exact text from the filing
On July 20, 2023, ImmunityBio, Inc. (the “Company”) entered into a stock purchase agreement (the “SPA”) with certain institutional investors (the “Investors”) for the purchase and sale of 14,569,296 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and warrants to purchase an additional 14,569,296 shares of Common Stock at an exercise price of $3.2946 per share, for a purchase price of $2.7455 per share and accompanying warrant, generating gross proceeds from the offering of approximately $40.0 million before deducting placement agent fees and other estimated offering expenses (the “Offering”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ImmunityBio, Inc. entered into placement agency agreement (the “PAA”) with Jefferies LLC (the “Placement Agent”) (effective 2023-07-20).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Jefferies LLC (the “Placement Agent”)
- Effective
- 2023-07-20
Exact text from the filing
On July 20, 2023, the Company also entered into a placement agency agreement (the “PAA”) with Jefferies LLC (the “Placement Agent”).
View on SEC.gov